Decoy Stock Rises After Announcing Up to $21 Million Private Placement Financing

U.S. CDC Says As Of August 6, 2,465 Confirmed Measles Cases Were Reported In U.S. In 2026; There Have Been 38 New Measles Outbreaks Reported In 2026, And 94% Of Confirmed Cases Are Outbreak-Associated

https://www.cdc.gov/measles/data-research/index.html

Decoy Therapeutics Announces The Expansion Of Its Intellectual Property Portfolio, Which Now Comprises Seven Patent Families

Portfolio now spans seven patent families and 19 pending applications across seven jurisdictions, protecting antiviral peptide conjugates, the methods used to make them, their formulations, and the design platform

Decoy Therapeutics shares are trading lower. The company announced that one of its D-MAV candidates demonstrates in vitro activity against wild-type Ebola Zaire virus in testing at the Texas Biomedical Research Institute.

Decoy Therapeutics Announces That One Of Its D-MAV Candidates Demonstrates In Vitro Activity Against Wild-Type Ebola Zaire Virus

Building on the result, Decoy has opened an exploratory program to design D-MAVs against filoviruses, including Ebola and Marburg. The candidate was engineered on Decoy's IMP3ACT™ platform to block coronavirus